Cellular and molecular cartography of muscle-invasive bladder cancer: Who benefits from neoadjuvant chemotherapy?
Muscle-invasive bladder cancer (MIBC) is characterised by significant molecular heterogeneity, with the tumour composition being further sculptured by local microenvironmental influences. This inherent complexity contributes to the divergent disease trajectories and the variable therapeutic susceptibility observed among patients. Consequently, there is an evident need for prognostic and predictive